Roche Plots Neuro Comeback with Promising Mid-Stage Alzheimer’s Data

Roche in a virtual investor event on Monday unveiled promising Phase Ib/IIa data for an investigational Alzheimer’s therapy that could define the pharma group’s neurology franchise in the coming years.